International guidelines recommend these medications as first-line therapies for patients with T2DM and confirmed atherosclerotic cardiovascular disease (ASCVD), heart failure, or CKD, recognizing the established efficacy of SGLT2 inhibitors across the full spectrum of heart failure phenotypes [6]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.